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Abstract
Background: In this study, we sought to evaluate the prevalence of metabolic syndrome (MS) in
a cohort of pregnant women with a wide range of glucose tolerance, prepregnancy risk factors for
MS during pregnancy, and the effects of MS in the outcomes in the mother and in the newborn.
Methods: One hundred and thirty six women with positive screening for gestational diabetes
mellitus (GDM) were classified by two diagnostic methods: glycemic profile and 100 g OGTT as
normoglycemic, mild gestational hyperglycemic, GDM, and overt GDM. Markers of MS were
measured between 2428th during the screening.
Results: The prevalence of MS was: 0%; 20.0%; 23.5% and 36.4% in normoglycemic, mild
hyperglycemic, GDM, and overt GDM groups, respectively. Previous history of GDM with or
without insulin use, BMI ≥ 25, hypertension, family history of diabetes in first degree relatives, non-
Caucasian ethnicity, history of prematurity and polihydramnios were statistically significant
prepregnancy predictors for MS in the index pregnancy, that by its turn increased the adverse
outcomes in the mother and in the newborn.
Conclusion: The prevalence of MS increases with the worsening of glucose tolerance; impaired
glycemic profile identifies pregnancies with important metabolic abnormalities even in the presence
of a normal OGTT, in patients that are not classified as having GDM.
Background
Short and long-term important consequences for the
fetus, the newborn and the mother can occur when gesta-
tional diabetes mellitus (GDM) is present [1,2]. Pregnant
women that show mild hyperglycemia, but do not meet
the criteria for GDM diagnosis can still present glucose-
mediated macrosomia, the same perinatal mortality rate
and adverse pregnancy and perinatal outcomes as those
with GDM [3-11].
Typically, a condition of insulin resistance develops in the
second and third trimester of pregnancy. The impairment
of insulin sensitivity makes pregnancy a diabetogenic con-
dition. Nonetheless, only 3 to 5% of women develop
GDM [12,13]. As it happens in type 2 diabetes mellitus
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emia is present, GDM is associated to both insulin resist-
ance and impaired insulin secretion [14-16]. DM2, MS
and GDM also share the same risk factors and have a cor-
responding prevalence within a given population and the
same genetic susceptibility [17]. Many of the known met-
abolic components of the MS are predictive of GDM,
which could be considered as one phase of the MS. MS is
referred to the association of hyperinsulinemia, insulin
resistance, visceral obesity, dyslipidemia, hypertension,
and DM2 or impaired glucose tolerance [18]. These fea-
tures increase the risk of atherosclerosis and coronary
heart disease [19,20]. It is not known whether mild
degrees of hyperglycemia are also associated to the com-
ponents of MS and adverse pregnancy outcomes.
Thus, the aims of this study were to evaluate the preva-
lence of MS through the presence of its physical and clin-
ical components in a cohort of pregnant women with a
wide range of glucose tolerance and to analyze prepreg-
nancy risk factors for the development of MS during preg-
nancy and its adverse impacts on pregnancy outcomes.
Research design, patients and methods
This study was approved by the Institutional Review
Board of the School of Medicine of Botucatu  São Paulo
State University  UNESP, Brazil; where it was conducted
from April 2004 through November 2005. One hundred
and thirty six women with singleton pregnancies were
assigned to participate if they presented a fasting glycemia
level ≥ 90 mg/dl and/or risk factors for developing GDM.
Between the 24th through 28th weeks of gestation, a 100 g
OGTT and a glycemic profile were performed. The cutoff
values for the OGTT were those proposed by Carpenter &
Coustan (fasting ≥ 95 mg/dl; 1 hour ≥ 180 mg/dl; 2 hours
≥ 155 mg/dl; 3 hours ≥ 140 mg/dl) [21] and for the glyc-
emic profile those proposed by Gillmer et al. (fasting ≥ 90
mg/dl and 1 hour post prandial ≥ 130 mg/dl) [22]. The
glycemic profile was performed a week after the OGTT.
Patients were taught on how to measure their glycemic
levels using a glucometer in the fasting state at 8:00
o'clock AM, then post-prandial at 10:00 o'clock AM, mid-
day, 2, 4 and 6 o'clock PM. If the results were borderline
(10 mg/dl higher or lower than the cutoff values) they
were repeated. After these procedures they were classified
in four groups:
IA Group  Normal OGTT and glycemic profile (normogly-
cemic or control group)
IB Group  Normal OGTT and abnormal glycemia profile
(mild hyperglycemic group)
IIA Group  Abnormal OGTT and normal glycemic profile
(gestational diabetes group)
IIB Group  Abnormal OGTT and glycemic profile (overt
gestational diabetes group)
Maternal characteristics such as age, parity, ethnicity, edu-
cational level, family income (Brazilian minimum wage),
weight and length at birth, weight and prepregnancy body
mass index (BMI), family's history of diabetes, hyperten-
sion, obesity, and dyslipidemia were recorded. At screen-
ing, weight, height, legs length, blood pressure, waist
circumference, and hip circumference were measured.
Obesity was defined as a prepregnancy body mass index
(BMI) ≥ 30 kg/m2. Hypertension was considered when a
systolic blood pressure >140 mmHg or a diastolic blood
pressure > 90 mmHg, on at least two occasions at least six
hours apart, was detected [23].
Blood samples were collected at the time the OGTT was
performed to determine fasting levels of glucose, HbA1c,
insulin, total, HDL-cholesterol, LDL- cholesterol, VLDL-
cholesterol, and triglycerides. A 75 g OGTT was performed
six weeks after delivery in those patients that presented
glucose intolerance during pregnancy to check if they had
returned or not to a normal glucose tolerant state.
All glucose determinations were conducted using glucose
oxidase method (Glucose-analyzer II Beckman, Fullerton,
CA, USA). Home blood glucose monitoring was per-
formed with an Accu-chek Advantage II Glucometer
(Roche Diagnostics GmbH, Mannheim, Germany). Total,
LDL-cholesterol, HDL-cholesterol, VLDL-cholesterol, and
triglycerides were measured by enzymatic colorimetric
assay (Vitros 250, Ortho-Clinical Diagnostics, Rochester,
New York, USA). HbA1c was determined by HPLC (high
performance liquid column) method (Dia-Stat analyzer,
Bio-Rad Laboratories, Hercules, CA, USA), and insulin
using a specific radioimmunoassay kit (Linco Research, St.
Charles, MO) with an intra and an interassay variation of
2.2 to 4.4% and 2.9 to 6.0%, respectively. Laboratory
quality standards were routinely evaluated.
Newborn data collected included birth weight, length,
ponderal index, gender, gestational age at delivery, Apgar
scores, perinatal morbidity, and congenital malforma-
tions. Births were defined as preterm if gestational age was
< 37 weeks. Ponderal index was calculated obtaining the
ratio between 100 times the weight (in grams) and the
cube of the length (in cm). The relation of newborns
weight to gestational age was done according to
Lubchenco's classification [24].
As there is no definition for MS in pregnancy, we adopted
the following: any one of the two primary criteria
[impaired glycemic profile and/or impaired OGTT, plus at
least two of the following secondary criteria: hypertension
(systolic blood pressure > 140 mmHg or a diastolic bloodPage 2 of 6
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hours apart); dyslipidemia (plasma triglycerides ≥ 2 SD
above the mean of the control group and/or low HDL-
Cholesterol < 39 mg/dl) and obesity (BMI ≥ 30 Kg/m2
and/or waist ≥ 2 SD above the mean of pregnant women
belonging to the control group)] [25-28].
The homeostasis model assessment (HOMA) was calcu-
lated to determine the degree of β-cell function (%) and
insulin sensitivity (or resistance) (%S), using a computer
program (HOMA2 model) that analyzes quantitatively
these data [29].
Statistical analysis
Data were presented as mean ± standard deviation (SD) or
percentages. Analysis of variance (ANOVA) with Tukey
post-test was performed to compare means for continu-
ous variables with normal distribution. Kruskal-Wallis
with Dunn post-test was performed when the supposition
of homocedasticity and normality of distribution were
not attempted. Fisher's exact test or Chi-square test plus
Odds ratio (with 95% CI) was performed for proportions
comparisons. The significance level adopted for all tests
was < 0.05.
Results
One hundred and thirty six patients were enrolled in the
study. All of them completed the protocol. Data were
available from 46 control group patients (IA group), 40
mild hyperglycemic (IB group), 17 GDM (IIA group) and
33 overt GDM (IIB group).
Women with overt diabetes were older (p < 0.002), had
lower education levels (p < 0.001), lower family income (p
< 0.001), were about 5 cm shorter (p < 0.001), and had
approximately 3 cm shorter legs (p = 0.014) than those
from the normoglycemic group. At birth, the overt GDM
women were shorter (p = 0.05) and weighted less (p =
0.042) than control group. Prepregnancy, they had higher
BMI (p = 0.001), larger waist (p < 0.001), higher systolic (p
= 0.003) and diastolic blood pressure (p = 0.003). At
screening, they had higher BMI (p < 0.001), larger waist (p
< 0.001), larger waist-to-hip ratio (p = 0.002), higher
systolic (p = 0.002) and diastolic (p = 0.02) blood pres-
sure, higher fasting glucose (p < 0.001), HbA1c (p < 0.001),
triglycerides (p = 0.016), VLDL (p = 0.037), and lower
HDL (p = 0.014) cholesterol. Women with mild hypergly-
cemia (IB group) also had lower education level (p <
0.001) and shorter legs (p = 0.014) than those from the
control group (Tables 1 and 2).
The results of HOMA are shown in Figure 1. The overt dia-
betes group showed significant increase in HOMA-IR val-
ues compared with control group (Fig. 1A; p < 0.05). They
also exhibited decreased β-cell function, and reduced
peripheral insulin sensitivity (as judged by the %β and
%S, respectively), when compared to the normoglycemic
group (Fig. 1B,C, respectively; p < 0.05).
There was a significantly increasing prevalence of MS from
the control group until the overt GDM group: 0.00%,
20.0%, 23.5%, 36.4% (p < 0.001 IA vs IB, IIA, IIB). The
prepregnancy independent predictors of MS during preg-
nancy were: previous history of GDM with insulin use OR
= 12.90 [95% CI (1.39119.76)] (p = 0.02), BMI > 25 OR =
11.00 [95% CI (4.1228.95)] (p < 0.001), hypertension OR
= 10.04 [95% CI (3.2537.97)] (p < 0.001), previous his-
tory of GDM without insulin use OR = 6.08 [95% CI
Table 1: Sociodemographic and clinical characteristics of the cohort according to glucose tolerance status (IA = normal glucose 
tolerance; IB = Impaired glycemic profile; IIA = Impaired 100 g OGTT; IIB = Impaired 100 g OGTT and glycemic profile).
Variables Groups p-value
IA IB IIA IIB
Number 46 40 17 33
Age (years) 28.7 ± 5.2 28.8 ± 6.4 31.4 ± 5.0 33.1 ± 5.6 0.002(1)
White (%) 89.1 77.5 82.4 60.6 0.025(2)
Education level (school years) 12.0 ± 3.6 10.7 ± 4.7 9.5 ± 4.6 7.1 ± 5.4 <0.001(3)
Family income 9.7 ± 5.4 7.7 ± 5.8 8.3 ± 5.4 3.5 ± 3.6 <0.001(4)
Diabetes in first degree relatives (%) 70.5 67.5 82.4 78.8 0.556
Smoking (%) 21.7 27.5 35.3 27.3 0.743
Maternal birth weight (g)* 3429 ± 617 3406 ± 480 3180 ± 808 2965 ± 757 0.042(5)
Maternal birth length (cm)* 48.9 ± 2.2 48.7 ± 1.9 47.6 ± 2.3 47.1 ± 3.5 0.05(6)
Maternal ponderal index* 2.8 ± 0.2 2.8 ± 0.2 2.9 ± 0.2 3.0 ± 0.6 0.224
(1) p < 0.05 IIB vs IA, IB;
(2) p < 0.01 IA vs IIB;
(3) p < 0.05 IIB vs IB, IIA, IA; IB vs IA;
(4) p < 0.01 IA vs IIB; IB vs IIB; IIA vs IIB;
(5) p < 0.05 IIB vs IB, IA;
(6) p < 0.05 IIB vs IA.
* Maternal weight, length and ponderal index at birthPage 3 of 6
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OR = 3.70 [95% CI (1.2011.38)] (p = 0.02), non-Cauca-
sian ethnicity OR = 2.94 [95% CI (1.236.67)] (p = 0.02),
history of prematurity OR = 2.84 [95% CI (1.067.57)] (p
= 0.03) and of polihydramnios OR = 2.57 [95% CI
(1.175.62)] (p = 0.02).
Acanthosis nigricans was the most prevalent physical
marker of insulin resistance at screening (19.6, 42.5, 58.8
and 69.7%; for IA, IB, IIA and IIB groups, respectively) (p
< 0.001 IA vs IB, IIA, IIB); followed by obesity (13.0, 40.0,
58.8 and 60.6%; for IA, IB, IIA and IIB groups, respec-
tively) (p < 0.001 IA vs IIA, IIB); hypertension (6.5, 17.5,
17.6 and 39.4%; for IA, IB, IIA and IIB groups, respec-
tively) (p < 0.005 IA vs IB, IIA, IIB), and large waist circum-
ference (2.2, 15.0, 35.4 and 24.2%; for IA, IB, IIA and IIB
groups, respectively) (p < 0.05 IA vs IB; IB vs IIB; p < 0.01
IA vs IIA, IIB).
Independently of glucose tolerance status, the whole
group was classified as having or not having MS, and the
prevalence of adverse maternal and perinatal outcomes
were analyzed. Women that presented MS showed a sig-
nificant association with the occurrence of preeclampsia
Table 2: Anthropometric (prepregnancy and at screening) and laboratory characteristics at screening according to glucose tolerance 
status during pregnancy
Variables Groups p-value
IA IB IIA IIB
Height (meter) 1.65 ± 0.07 1.64 ± 0.05 1.61 ± 0.05 1.60 ± 0.05 0.001(1)
Legs length (cm) 76.0 ± 4.8 75.3 ± 4.0 73.3 ± 4.1 73.1 ± 4.1 0.014(2)
BMI
Prepregnancy 23.1 ± 4.5 25.8 ± 6.1 27.8 ± 7.6 28.5 ± 6.9 0.001(3)
At screening 25.6 ± 4.3 29.3 ± 6.1 31.0 ± 6.9 31.4 ± 6.0 <0.001(4)
Waist
Prepregnancy 69.6 ± 5.1 81.5 ± 11.3 90.3 ± 18.6 101.8 ± 15.1 <0.001(5)
At screening 95.9 ± 10.1 104.5 ± 11.3 107.6 ± 14.4 108.2 ± 9.8 <0.001(6)
Waist-to-hip ratio
Prepregnancy 0.76 ± 0.06 0.76 ± 0.05 0.86 ± 0.11 0.87 ± 0.11 0.040
At screening 0.93 ± 0.07 0.95 ± 0.07 0.97 ± 0.04 0.99 ± 0.07 0.002 (7)
Systolic blood pressure (mmHg)
Prepregnancy 108.4 ± 7.8 115.5 ± 23.3 114.7 ± 14.1 125.4 ± 25.8 0.003(8)
At screening 107.7 ± 9.9 111.0 ± 12.5 114.7 ± 11.7 120.6 ± 17.6 0.002(9)
Diastolic blood pressure (mmHg)
Prepregnancy 71.0 ± 8.2 75.0 ± 14.1 75.8 ± 9.3 81.2 ± 12.9 0.003(10)
At screening 71.5 ± 9.2 74.5 ± 10.8 76.4 ± 11.1 79.3 ± 12.2 0.02(11)
At screening
Fasting glucose(mg/dl) 73.7 ± 8.7 74.8 ± 9.6 87.2 ± 11.7 114.4 ± 23.6 <0.001(12)
HbA1c (%) 4.57 ± 0.45 4.95 ± 0.59 5.15 ± 0.71 5.98 ± 1.00 <0.001(13)
Total cholesterol(mg/dl) 229.2 ± 43.5 236.7 ± 44.5 221.4 ± 42.3 195.5 ± 43.0 0.001(14)
LDL cholesterol(mg/dl) 124.2 ± 41.5 130.2 ± 37.8 111.6 ± 34.6 94.2 ± 33.0 0.001(15)
HDL cholesterol(mg/dl) 69.0 ± 16.9 66.1 ± 16.4 73.1 ± 21.3 57.8 ± 16.2 0.014(16)
VLDL cholesterol(mg/dl) 34.8 ± 12.0 39.4 ± 13.3 36.5 ± 13.9 43.4 ± 11.7 0.037(17)
Triglycerides (mg/dl) 174.3 ± 60.4 215.7 ± 131.7 182.8 ± 69.5 217.3 ± 58.5 0.016(18)
(1) p < 0.05 IIB vs IB, IA; IIA vs IA;
(2) p < 0.05 IA vs IIB, IIA, IB;
(3) p < 0.05 IA vs IIA, IIB;
(4) p < 0.05 IA vs IB, IIA, IIB;
(5) p < 0.05 IA vs IB, IIA, IIB;
(6) p < 0.05 IA vs IB, IIA, IIB;
(7) p < 0.05 IA vs IIA, IIB; IB vs IIB;
(8) p < 0.01 IA vs IIB;
(9) p < 0.01 IA vs IIB;
(10) p < 0.01 IA vs IIB;
(11) p < 0.05 IA vs IIB;
(12) p < 0.001 IA vs IIB, IB vs IIB; p < 0.01 IA vs IIA; p < 0.05 IB vs IIA, IIA vs IIB;
(13) p < 0.001 IA vs IIB; IB vs IIB;
(14) p < 0.05 IIB vs IIA, IA, IB;
(15) p < 0.05 IIB vs IA, IB;
(16) p < 0.05 IIB vs IA, IIA;
(17) p < 0.05 IA vs IIB;
(18) p < 0.05 IA vs IIB;Page 4 of 6
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spring of mothers with MS presented significantly higher
prevalence of LGA OR = 2.97 [95% CI (1.048.47)] (p =
0.0409), overweight (ponderal index) OR = 4.08 [95% CI
(1.6510.18)] (p = 0.001), Apgar score < 7 at 1 min OR =
6.06 [95% CI (1.4526.94)] (p = 0.0083) and 2 min OR =
4.81 [95% CI (1.2119.09)] (p = 0.041), prematurity OR =
3.37 [95% CI (1.308.71)] (p = 0.031), and any kind of
adverse perinatal outcomes OR = 2.88 [95% CI
(1.226.84)] (p = 0.0135).
Discussion
There is an association between the worsening of glucose
tolerance with an increasing prevalence of MS. The wors-
ening of glucose tolerance was directly associated with age
[30], non-Caucasian ethnicity, lower education levels,
lower family income [31], lower weight and length at
birth [32], lower height and shorter legs in adulthood
[33], higher BMI, larger waist, larger waist-to-hip ratio
[28,34], higher systolic, and diastolic blood pressure [35].
Laboratory findings of lower HDL cholesterol and higher
levels of VLDL cholesterol and triglycerides were also asso-
ciated with the worsening of glucose tolerance. Many of
these features are components of MS. This led us to
explore the metabolic nature of mild gestational hypergly-
cemia and GDM as part of the insulin resistance syn-
drome.
Using the HOMA2 model to assess beta cell function and
peripheral insulin sensitivity, we have found that preg-
nant women that presented any degree of glucose intoler-
ance also showed higher degree of insulin resistance at
screening. Patients that presented mild hyperglycemia
(impaired glycemic profile and normal OGTT) showed
higher values of HOMA-IR and lower peripheral insulin
sensitivity, although not statistically significant, com-
pared with the control group, showing that besides pre-
senting insulin resistance, they also had a compensatory
hyperinsulinemia. The GDM group (impaired OGTT and
normal glycemic profile) had high HOMA-IR values,
which were not also statistically significant; however
peripheral insulin sensitivity was significantly decreased,
pointing to the presence of some insulin action defi-
ciency. Finally, the overt GDM group (both impaired
tests) showed the highest values of HOMA-IR probably
due to a decreased insulin peripheral action and impaired
β-cell function, what points to the presence of both patho-
physiological mechanisms that are present in GDM as
well as in DM2: insulin resistance and insulin deficiency
(Figure 1).
Our study was limited by the small number of partici-
pants; so more research is warranted analyzing more
patients.
Conclusion
In conclusion, our data support: that the prevalence of MS
increases with the worsening of glucose tolerance; the
important role of glycemic profile as a diagnostic test to
identify metabolic abnormalities related to MS in preg-
nancy even in the presence of a normal OGTT, in patients
that are not currently classified as having GDM.
Abbreviations
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Evaluation of peripheral insulin sensitivity and β-cell function in patients by HOMA2 modelFig re 1
Evaluation of peripheral insulin sensitivity and β-cell function in patients by HOMA2 model. These graphs show: 
(A) significant increase of HOMA-IR values (A), decreased β-cell-function (B), and decreased peripheral insulin sensitivity (C) 
in IIB group when compared with IA group. IIA group of patients also exhibited decreased peripheral insulin sensitivity, com-
pared with IA group (C). The values are mean ± SD. asignificantly different vs IA; bvs IB. p < 0.05.Page 5 of 6
(page number not for citation purposes)
Diabetology & Metabolic Syndrome 2009, 1:3 http://www.dmsjournal.com/content/1/1/3Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright




C.A.N., L.J., A.R. and M.V.C.R participated in the design of
the study. C.A.N., M.A.T., B.G., A.D. and M.V.C.R per-
formed the data collection. A.R. and A.D. performed the
statistical analysis. C.A.N. and A.R. wrote the paper. All
authors read and approved the final manuscript.
References
1. Bo Simona, Menato G, Gallo M-L, et al.: Mild gestational hyperg-
lycemia, the metabolic syndrome and adverse neonatal out-
comes.  Acta Obstet Gynecol Scand 2004, 83:335-340.
2. Dabelea D, Pettit D: Long-term implications: child and adult.  In
Textbook of Diabetes and Pregnancy Edited by: Hod M, Jovanovic L, Di
Renzo GC, Leiva A, Langer O. Martin Dunitz, London; 2003:628. 
3. Hod M, Merlob P, Friedman S, Schoenfeld A, Ovadia J: Gestational
diabetes mellitus: a survey of perinatal complications in the
1980s.  Diabetes 1991, 40:74-78.
4. Rudge MVC, Calderon IMP, Ramos MD, et al.: Hiperglicemia
materna diária diagnosticada pelo perfil glicêmico: um prob-
lema de saúde pública materno e perinatal.  Rev Bras Ginecol
Obstet 2005, 27(11):691-697.
5. Sermer M, Naylor CD, Gare Dj, Kenshole AB, Ritchie JW, Farine D,
et al.: For the Toronto Tri-Hospital Gestational Diabetes
Investigators. Impact of increasing carbohydrate intolerance
on maternal-fetal outcomes in 3637 women without gesta-
tional diabetes. The Toronto tri-Hospital Gestational Diabe-
tes Project.  Am J Obstet Gynecol 1995, 173:146-156.
6. Mello G, Parretti E, Mecacci F, Lucchetti R, Cianciulli D, Lagazio O, et
al.: Anthropometric characteristics of full-term infants:
effects of varying degrees of 'normal' glucose metabolism.  J
Perinat Med 1997, 25:197-204.
7. Bevier WC, Fischer R, Jovanovic L: Treatment of women with an
abnormal glucose challenge test (but a normal oral glucose
tolerance test) decreases the prevalence of macrosomia.  Am
J Perinatol 1999, 16:269-275.
8. Vambergue A, Nuttens MC, Verier-Mine O, Dognin C, Cappoen JP,
Fontaine P: Is mild gestational hyperglycemia associated with
maternal and neonatal complications? The Digest study.  Dia-
bet Med 2000, 17:203-208.
9. Aberg A, Rydhstroem H, Frid A: Impaired glucose tolerance
associated with adverse pregnant outcome: a population
based study in southern sweden.  Am J Obstet Gynecol 2001,
184:77-83.
10. Scholl TO, Sowers MF, Chen X, Lenders C: Maternal glucose con-
centration influences fetal growth, gestation, and pregnancy
complications.  Am J Epidemiol 2001, 154:514-520.
11. Rudge MVC, Calderon IMP, Ramos MD, Abbade JF, Rugolo LMSS:
Perinatal outcome of pregnancies complicated by diabetes
and by maternal daily hyperglycemia not related to diabetes.
A retrospective 10 year analysis.  Gynecol Obst Invest 2000,
50:108-112.
12. King H: Epidemiology of glucose intolerance and gestational
diabetes in women of child bearing age.  Diabetes Care 1998,
21(Suppl 2):B9-B13.
13. Engelgau MM, Herman WH, Smith PJ, German RR, Aubert RE: The
epidemiology of diabetes and pregnancy in the U.S. 1988.
Diabetes Care 1995, 18:1029-1033.
14. Ryan EA, O'Sullivan MJ, Skyler JS: Insulin action during preg-
nancy: studies with the euglycemic clamp technique.  Diabetes
1985, 34:380-389.
15. Catalano PM, Tysbir ED, Wolfe RR, Calles J, Roman NM, Amini SB, et
al.: Carbohydrate metabolism during pregnancy in control
subjects and women with gestational diabetes.  Am J Physiol
1993, 264:E60-E67.
16. Kuhl C: Insulin secretion and insulin resistance in pregnancy
and GDM:implications for diagnosis and management.  Diabe-
tes 1991, 40:18-24.
17. Ben-Haroush A, Yogev Y, Hod M: Epidemiology of gestational
diabetes mellitus and its association with type 2 diabetes.
Diabet Med 2003, 21:103-113.
18. Clark CM, Qiu C, Amerman B, Porter B, Fineberg N, Aldasouqi S, et
al.: Gestational diabetes: should it be added to the syndrome
of insulin resistance?  Diabetes Care 1997, 20(5):867-871.
19. Meyers-Seifer CH, Vohr BR: Lipid levels in former gestational
diabetic mothers.  Diabetes care 1996, 19:1351-1356.
20. Davis CL, Gutt M, Llabre MM, Marks JB, O' Sullivan MJ, Potter JE, et
al.: History of gestational diabetes, insulin resistance and cor-
onary risk.  J Diabetes Complic 1999, 4:216-223.
21. Carpenter MW, Coustan DR: Criteria for screening test for ges-
tational diabetes.  Am J Obstet Gynecol 1982, 144:768-773.
22. Gillmer MDG, Beard RW, Brooke FM, Oakley NW: Carbohydrate
metabolism in pregnancy.  Br Med J 1975, 3:399-404.
23. Davey DA, Mac Gyllivray I: The classification and a definition of
the hypertensive disorders of pregnancy.  Am J Obstet Gynecol
1984, 158:892.
24. Lubchenco LO, Hansman C, Boyd E: Intrauterine growth in
length and head circumference as estimated from live births
at gestational ages from 26 to 42 weeks.  Pediatrics 1966,
37(3):403-408.
25. Alberti KG, Zimmet PZ: Definition, diagnosis and classification
of diabetes mellitus and its complications. Part I, Diagnosis
and classification of diabetes mellitus provisional report of a
WHO consultation.  Diabet Med 1998, 15:539-553.
26. Balkau B, Charles MA: for the European Group for the Study of
Insulin Resistance (EGIR). Comment of the provisional
report from the WHO consultation.  Diabetic Med 1999,
16:442-443.
27. The IDF consensus worldwide definition of the metabolic
syndrome   [http://www.idf.org/webdata/docs/
IDF_Metasyndromedefinition.pdf]. Accessed May 1st, 2007
28. Branchtein L, Schmidt MI, Mengue SS, Reichelt AJ, Matos MCG, Dun-
can BB: Waist circumference and waist-to-hip ratio are
related to gestational glucose tolerance.  Diabetes Care 1997,
20:509-511.
29. Levy JC, Mathews DR, Hermans MP: Correct homeostasis model
assessment (HOMA) evaluation uses the computer pro-
gram.  Diabetes Care 1998, 21(12):2191-2.
30. Lao TT, Ho L, Chan BCP, Leung W: Maternal age and prevalence
of gestational diabetes mellitus.  Diabetes Care 2006,
29(4):948-949.
31. Wadsworth MEJ, Hardy RJ, Paul AA, Marshall SF, Cole TJ: Leg and
trunk length at 43 years in relation to childhood health, diet
and family circumstances; evidence from the 1946 national
birth cohort.  Int J Epidemiol 2002, 31:383-390.
32. Seghieri G, Anichini R, De Bellis A, Alviggi L, Franconi F, Breschi MC:
Relationship between gestational diabetes mellitus and low
maternal birth weight.  Diabetes Care 2002, 25(10):1761-1765.
33. Moses RG, Mackay MT: Gestational diabetes: is there a rela-
tionship between leg length and glucose tolerance?  Diabetes
Care 2004, 27(5):1033-1035.
34. Langer O, Yogev Y, Xenakis EMJ, Brustman L: Overweight and
obese in gestational diabetes: The impact of pregnancy out-
come.  Am J Obstet Gynecol 2005, 192:1768-1776.
35. Bryson CL, Ioannou GN, Rulyak SJ, Critchlow C: Association
between gestational diabetes and pregnancy-induced hyper-
tension.  Am J Epidemiol 2003, 158:1148-1153.Page 6 of 6
(page number not for citation purposes)
